Providing Optimal Care for Patients With Advanced Renal Cell Carcinoma Using New Clinical Insights and Shared Decision Making
Source: Providing Optimal Care for Patients With Advanced Renal Cell Carcinoma Using New Clinical Insights and Shared Decision Making

Video Module

Listen to this expert-led, on-demand Webcast in conjunction with our downloadable slideset to get the latest information on optimal treatment for your patients with advanced RCC.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Explain treatment options to patients with advanced renal cell carcinoma, including the efficacy and toxicity profiles of various treatment options
  • Select appropriate treatment for advanced renal cell carcinoma based on the available clinical data, patient comorbidities, and patient preference through an shared decision making process
  • Manage potential adverse events associated with treatment
  • Provide appropriate care and counsel for patients and their families
CCO Video Modules contain video commentary by our esteemed faculty. Complete the CME posttest and evaluation after watching the presentation.
 

Program Directors

  • Michael T. Halpern
    MD, PhD, MPH
    Thomas E. Hutson
    DO, PharmD, FACP
    Brian Rini
    MD, FACP

Faculty

  • Michael B. Atkins
    MD
    Toni K. Choueiri
    MD
    Daniel M. Geynisman
    MD
    Hans-Joerg Hammers
    MD, PhD
    Brian E. Lewis
    MD, MPH
    Jaime R. Merchan
    MD
    Robert Motzer
    MD
    Charles J. Ryan
    MD
    Ulka Vaishampayan
    MD
    Martin H. Voss
    MD

Credit Information

  • Release Date:
    January 20, 2016
  • Expiration Date:
    January 19, 2017
  • Physicians:
    maximum of 1.0 AMA PRA Category 1 Credit
  • Registered Nurses:
    1.0 Nursing contact hour

Information on this Educational Activity

Disclosure of Conflicts of Interest

The Annenberg Center assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by the Annenberg Center for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. The Annenberg Center is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

 

Program Directors

Michael T. Halpern, MD, PhD, MPH

Associate Professor
Department of Public Health Policy and Management
Mel and Enid Zuckerman College of Public Health
University of Arizona
Tucson, Arizona

Michael T. Halpern, MD, PhD, MPH, has disclosed that he has received consulting fees and funds for research support from AbbVie.

 

Thomas E. Hutson, DO, PharmD, FACP

Professor of Medicine
Department of Medicine
Texas A&M College of Medicine
Director, GU Oncology Program
Texas Oncology
Baylor-Sammons Cancer Center
Dallas, Texas

Thomas E. Hutson, DO, PharmD, FACP, has disclosed that he has received consulting fees from Bayer, Novartis, and Pfizer; fees for non-CME/CE services received directly from a commercial interest or their agents (eg, speaker bureaus) from Astellas, Bayer, Novartis, and Pfizer; and funds for research support from Novartis and Pfizer.

 

Brian Rini, MD, FACP

Staff Physician
Department of Solid Tumor Oncology and Urology
Cleveland Clinic Taussig Cancer Institute
Professor of Medicine
CCR/CWRU Lerner College of Medicine
Cleveland, Ohio

Brian Rini, MD, FACP, has disclosed that he has received consulting fees from Bristol-Myers Squibb, Merck, Novartis, and Pfizer and funds for research support from Bristol-Myers Squibb, Genentech, and Pfizer.

 

Faculty

Michael B. Atkins, MD


Deputy Director
Lombardi Comprehensive Cancer Center
Georgetown University
Washington, DC

Michael B. Atkins, MD, has disclosed that he has received consulting fees from Bristol-Myers Squibb, Genentech, GlaxoSmithKline, Merck, Novartis, and Pfizer.
 

Toni K. Choueiri, MD


Associate Professor of Medicine
Harvard Medical School
Director, Kidney Cancer Center
Clinical Director, Lank Center for Genitourinary Oncology
Department of Medical Oncology
Dana-Farber Cancer Institute
Boston, Massachusetts

Toni K. Choueiri, MD, has disclosed that he has received consulting fees from Bayer, GlaxoSmithKline, Merck, Novartis, and Pfizer and institutional funds for research support from AstraZeneca, Bristol-Myers Squibb, Exelixis, GlaxoSmithKline, Merck, Novartis, Pfizer, Roche, and Tracon.
 

Daniel M. Geynisman, MD


Assistant Professor of Medical Oncology
Department of Hematology/Oncology
Fox Chase Cancer Center
Philadelphia, Pennsylvania

Daniel M. Geynisman, MD, has disclosed that he has received consulting fees from Novartis, Pfizer, and Prometheus and funds for research support from Pfizer.
 

Hans-Joerg Hammers, MD, PhD


Assistant Professor
Department of Oncology
Johns Hopkins
Baltimore, Maryland

Hans-Joerg Hammers, MD, PhD, has disclosed that he has received consulting fees from Bristol-Myers Squibb, Pfizer, and Prometheus and funds for research support from Bristol-Myers Squibb, GlaxoSmithKline, NewLink, and Pfizer.
 

Brian E. Lewis, MD, MPH


Assistant Professor of Clinical Medicine
Department of Hematology and Medical Oncology
Tulane University School of Medicine
New Orleans, Louisiana

Brian E. Lewis, MD, MPH, has no real or apparent conflicts of interest to report.
 

Jaime R. Merchan, MD


Associate Professor of Medicine
Division of Hematology-Oncology
Department of Medicine
University of Miami - SCCC
Miami, Florida

Jaime R. Merchan, MD, has disclosed that he has received funds for research support from Acceleron, Exelixis, GlaxoSmithKline, Pfizer, and Tracon.
 

Robert Motzer, MD


Attending Physician
Memorial Sloan-Kettering Cancer Center
New York, New York

Robert Motzer, MD, has disclosed that he has received consulting fees from Novartis and Pfizer.
 

Charles J. Ryan, MD


Professor of Clinical Medicine and Urology
Thomas Perkins Distinguished Professor in Cancer Research
Program Leader,
Genitourinary Medical Oncology
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, California

Charles J. Ryan, MD, has disclosed that he has received consulting fees from AstraZeneca, Bayer, Medivation, and Tokai; fees for non-CME/CE services received directly from a commercial interest or their agents (eg, speaker bureaus) from Janssen; and funds for research support from Karyopharm.
 

Ulka Vaishampayan, MD


Chair, GU Oncology Team
Director, Phase I Clinical Trial Program
Karmanos Cancer Institute
Professor of Oncology
Wayne State University
Detroit, Michigan

Ulka Vaishampayan, MD, has disclosed that she has received consulting fees, fees for non-CME/CE services received directly from a commercial interest or their agents (eg, speaker bureaus), and funds for research support from Novartis and Pfizer.
 

Martin H. Voss, MD


Assistant Attending
Division of Solid Tumor Genitourinary
Attending Physician
Division of GU Medical Oncology
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Martin H. Voss, MD, has disclosed that he has received consulting fees from Bayer, GlaxoSmithKline, and Novartis; funds for research support from Bristol-Myers Squibb; and honorarium from Novartis.
 

Staff

Kristen M. Rosenthal, PhD


Managing Editor

Kristen Rosenthal, PhD, has no real or apparent conflicts of interest to report.
 

Kiran Mir-Hudgeons, PhD


Clinical Editor

Kiran D. Mir-Hudgeons, PhD, has no real or apparent conflicts of interest to report.
 

Kevin Obholz, PhD


Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no real or apparent conflicts of interest to report.
 

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

The following planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, RN, BSN and Jan Schultz, RN, MSN, CHCP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Charles E. Willis, MBA, Director of Continuing Education, Amanda Sewell, MBA, Manager of Continuing Education, Debbie Price, Registration Database Administrator, and Alma Perez, Accreditation Specialist from the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Annenberg Center, Postgraduate Institute for Medicine (PIM), Clinical Care Options, and activity supporters do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the Annenberg Center, PIM, Clinical Care Options, and activity supporters. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

 

Target Audience

The target audience includes physicians, registered nurses, and other healthcare providers who comprise the multidisciplinary care team for patients with renal cell carcinoma.


Goal

The goal of this program is to improve outcomes for patients with advanced renal cell carcinoma by providing clinicians with expert insights on applying new clinical data within a shared decision making framework.


Learning Objectives

Upon completion of this activity, participants should be able to:

  • Explain treatment options to patients with advanced renal cell carcinoma, including the efficacy and toxicity profiles of various treatment options
  • Select appropriate treatment for advanced renal cell carcinoma based on the available clinical data, patient comorbidities, and patient preference through an shared decision making process
  • Manage potential adverse events associated with treatment
  • Provide appropriate care and counsel for patients and their families
 

Physician Continuing Medical Education

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC. The Annenberg Center for Health Sciences at Eisenhower is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 

Nursing Continuing Education

Accreditation Statement

Annenberg Center for Health Sciences is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Credit Designation

1.0 contact hour may be earned for successful completion of this activity.

 

Commercial Support


This program is supported by educational grants from Pfizer Inc., and Novartis Pharmaceuticals Corporation.

 

Program Medium


This program has been made available online.

 

Site Requirements


  • Internet Explorer 7+, Firefox 3+, Safari 3+, or Chrome
  • JavaScript enabled
  • 1024x768+ screen resolution
  • Adobe Flash Player
 

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1 hour. To successfully complete this activity and receive credit, participants must follow these steps during the period from January 20, 2016, through January 19, 2017:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME activities completed can be found on the "CME Manager" page. There are no costs/fees for this activity.